3.6.21
Amyl Therapeutics closes €18.3 million
Amyl Therapetucs had joined the 2024 AD/PDconference in Lisbon to learn about progress with Immunotherapeutics targeting abeta, TAU and alpha syn and also to consolidate exciting collaborations with research and development teams involved in in vitro and exvivo assays and models in neurodegenerative diseases. Exciting time!